nach oben

Erschienen in:

01.09.2014 | Original Article

The introduction of anti-phosphatidylserine/prothrombin autoantibodies in the laboratory diagnostic process of anti-phospholipid antibody syndrome: 6 months of observation

verfasst von: Martina Fabris, Roberta Giacomello, Alessandra Poz, Lisa Pantarotto, Nicolanna Tanzi, Francesco Curcio, Elio Tonutti

Erschienen in: Autoimmunity Highlights | Ausgabe 2/2014

Einloggen, um Zugang zu erhalten

Abstract

Purpose

To evaluate the impact of the introduction of the anti-phosphatidylserine/prothrombin autoantibodies (aPS/PT) in the laboratory diagnostic process of anti-phospholipid antibody syndrome (APS).

Methods

Four hundred and twenty-one patients (71.5 % females; 53 ± 15 years) presenting a medical prescription for aPS/PT antibodies were consecutively enrolled in the study from March 2013 to August 2013. During the same period, aPS/PT were additionally investigated in a selected series of 62 patients characterized by difficult lupus anticoagulant (LA) tests interpretation and in a retrospective series of 52 LA positive cases with available data about anti-prothrombin (aPT) antibodies. The aPS/PT antibodies, as well as the anti-cardiolipin (aCL), the anti-β2 glycoprotein I (aβ2GPI) and the aPT antibodies were analyzed by ELISA. LA was tested according to the recommended criteria, performing both the screen and the confirm steps.

Results

Overall, aPS/PT IgM positive (>30 U/ml) and/or IgG frankly positive (>40 U/ml) antibodies were found in 49/421 (11.6 %) cases. Among the LA positive patients, we found 56.1 % aPS/PT positive versus 31.7 % aCL and/or aβ2GPI positive cases, with limited (17.1 %) simultaneous positivity. The PS/PT complex resulted the newly recognized specificity in about 27 % of patients recruited from the subset with difficult LA test interpretation. Compared to aPT antibodies, the aPS/PT antibodies displayed a much higher sensitivity (55.8 versus 15.4 %) in LA positive patients.

Conclusions

The introduction of aPS/PT antibodies in the diagnostic process of APS is highly recommended, since they disclose a notable diagnostic performance and a high correlation with LA activity, such that they can be a viable alternative.

Miyakis S, Lockshin MD, Atsumi T, Branch DW, Brey RL, Cervera R et al (2006) International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 4:295–306PubMedCrossRef

Alessandri C, Conti F, Conigliaro P, Mancini R, Massaro L, Valesini G (2009) Seronegative autoimmune diseases. Ann N Y Acad Sci 1173:52–59PubMedCrossRef

Ortona E, Capozzi A, Colasanti T, Conti F, Alessandri C, Longo A et al (2010) Vimentin/cardiolipin complex as a new antigenic target of the antiphospholipid syndrome. Blood 116(16):2960–2967PubMedCrossRef

Zˇigon P, Ambrozˇicˇ A, Cˇucˇnik S, Kveder T, Rozman B, Bozˇicˇ B (2011) Modified phosphatidylserine-dependent antiprothrombin ELISA enables identification of patients negative for other antiphospholipid antibodies and also detects low avidity antibodies. Clin Chem Lab Med 49:1011–1118

Atsumi T, Ieko M, Bertolaccini ML, Ichikawa K, Tsutsumi A, Matsuura E, Koike T (2000) Association of autoantibodies against the phosphatidylserine-prothrombin complex with manifestations of the antiphospholipid syndrome and with the presence of lupus anticoagulant. Arthritis Rheum 43(9):1982–1993PubMedCrossRef

Bertolaccini ML, Amengual O, Atsumi T, Binder WL, de Laat B, Forastiero R et al (2011) ‘Non-criteria’ aPL tests: report of a task force and preconference workshop at the 13th International Congress on Antiphospholipid Antibodies, Galveston, TX, USA, April 2010. Lupus 20:191–205PubMedCrossRef

Hoxha A, Ruffatti A, Tonello M, Bontadi A, Salvan E, Banzato A et al (2012) Antiphosphatidylserine/prothrombin antibodies in primary antiphospholipid syndrome. Lupus 21:787–789PubMedCrossRef

Syuto T, Shimizu A, Takeuchi Y, Tanaka S, Hasegawa M, Nagai Y et al (2009) Association of antiphosphatidylserine/prothrombin antibodies with neuropsychiatric systemic lupus erythematosus. Clin Rheumatol 28(7):841–845PubMedCrossRef

Kawakami T, Yamazaki M, Mizoguchi M, Soma Y (2007) High titer of anti-phosphatidylserine-prothrombin complex antibodies in patients with cutaneous polyarteritis nodosa. Arthritis Rheum 57(8):1507–1513PubMedCrossRef

10.

Hasegawa M, Sato S, Yanaba K, Komura K, Yamazaki M, Takehara K (2004) Autoantibodies against phosphatidylserine-prothrombin complex in patients with systemic sclerosis. Ann Rheum Dis 63(11):1514–1517PubMedPubMedCentralCrossRef

11.

Jaskowski TD, Wilson AR, Hill HR, Branch WD, Tebo AE (2009) Autoantibodies against phosphatidylserine, prothrombin and phosphatidylserine-prothrombin complex: identical or distinct diagnostic tools for antiphospholipid syndrome? Clin Chim Acta 410(1–2):19–24PubMedCrossRef

12.

Sciascia S, Sanna G, Murru V, Roccatello D, Khamashta MA, Bertolaccini ML (2014) Anti-prothrombin (aPT) and anti-phosphatidylserine/prothrombin (aPS/PT) antibodies and the risk of thrombosis in the antiphospholipid syndrome. A systematic review. Thromb Haemost 111(2):354–364PubMedCrossRef

13.

Sciascia S, Murru V, Sanna G, Roccatello D, Khamashta MA, Bertolaccini ML (2012) Clinical accuracy for diagnosis of antiphospholipid syndrome in systemic lupus erythematosus: evaluation of 23 possible combinations of antiphospholipid antibody specificities. J Thromb Haemost 10(12):2512–2518PubMedCrossRef

14.

Pregnolato F, Chighizola CB, Encabo S, Shums Z, Norman GL, Tripodi A et al (2013) Anti-phosphatidylserine/prothrombin antibodies: an additional diagnostic marker for APS? Immunol Res 56(2–3):432–438PubMedCrossRef

15.

Pengo V, Tripodi A, Reber G, Rand JH, Ortel TL, Galli M, De Groot PG (2009) Update of the guidelines for lupus anticoagulant detection. Subcommittee on lupus anticoagulant/antiphospholipid antibody of the scientific and standardisation committee of the international society on thrombosis and haemostasis. J Thromb Haemost 7:1737–1740PubMedCrossRef

16.

Tripodi A, Chantarangkul V, Clerici M, Palmucci C, Bison E, Banzato A et al (2011) Standardization of lupus anticoagulant. Feasibility study of a calibration model to minimize between-method variability. Thromb Res 127:589–594PubMedCrossRef

Titel: The introduction of anti-phosphatidylserine/prothrombin autoantibodies in the laboratory diagnostic process of anti-phospholipid antibody syndrome: 6 months of observation
verfasst von: Martina Fabris
Roberta Giacomello
Alessandra Poz
Lisa Pantarotto
Nicolanna Tanzi
Francesco Curcio
Elio Tonutti
Publikationsdatum: 01.09.2014
Verlag: Springer International Publishing
Erschienen in: Autoimmunity Highlights / Ausgabe 2/2014
Print ISSN: 2038-0305
Elektronische ISSN: 2038-3274
DOI: https://doi.org/10.1007/s13317-014-0061-3

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Bessere Prognose mit links- statt rechtsseitigem Kolon-Ca.

06.05.2024 Kolonkarzinom Nachrichten

Menschen mit linksseitigem Kolonkarzinom leben im Mittel zweieinhalb Jahre länger als solche mit rechtsseitigem Tumor. Auch aktuell ist das Sterberisiko bei linksseitigen Tumoren US-Daten zufolge etwa um 11% geringer als bei rechtsseitigen.

Echinokokkose medikamentös behandeln oder operieren?

06.05.2024 DCK 2024 Kongressbericht

Die Therapie von Echinokokkosen sollte immer in spezialisierten Zentren erfolgen. Eine symptomlose Echinokokkose kann – egal ob von Hunde- oder Fuchsbandwurm ausgelöst – konservativ erfolgen. Wenn eine Op. nötig ist, kann es sinnvoll sein, vorher Zysten zu leeren und zu desinfizieren.

Aquatherapie bei Fibromyalgie wirksamer als Trockenübungen

03.05.2024 Fibromyalgiesyndrom Nachrichten

Bewegungs-, Dehnungs- und Entspannungsübungen im Wasser lindern die Beschwerden von Patientinnen mit Fibromyalgie besser als das Üben auf trockenem Land. Das geht aus einer spanisch-brasilianischen Vergleichsstudie hervor.

Wo hapert es noch bei der Umsetzung der POMGAT-Leitlinie?

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen